PHAT Phathom Pharmaceuticals, Inc.
Healthcare · Market cap: $490.3M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $0 |
| 2022-Q2 | $415.1K | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $0 | $35.4K |
| 2023-Q1 | $73.6K | $77.3K |
| 2023-Q2 | $191.2K | $74.5K |
| 2023-Q3 | $0 | $0 |
| 2023-Q4 | $58.6K | $126.3K |
| 2024-Q1 | $0 | $30.2M |
| 2024-Q2 | $0 | $38.1K |
| 2024-Q3 | $0 | $575.1K |
| 2024-Q4 | $180.3K | $19.3K |
| 2025-Q1 | $44.2K | $221.3K |
| 2025-Q2 | $216.9K | $16.7K |
| 2025-Q3 | $0 | $19.7K |
| 2025-Q4 | $0 | $7.1K |
| 2026-Q1 | $0 | $0 |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $0 | $0 |
| 2026-Q4 | $0 | $0 |
Bought$1.2M21 buy days
Sold$31.4M26 sell days
Net insider flow-$30.2Mnet selling · 5 years
Latest trade2025-11-03Breedlove Robert Charles
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2025-11-03 | Sell | Breedlove Robert Charles | Other officer | 524 | $13.51 | $7.1K | 1 |
| 2025-09-05 | Sell | Breedlove Robert Charles | Other officer | 461 | $12.09 | $5.6K | 1 |
| 2025-07-16 | Sell | Breedlove Robert Charles | Other officer | 1,692 | $8.36 | $14.1K | 1 |
| 2025-05-21 | Buy | Topper James N | Director | 3,780 | $3.86 | $14.6K | 1 |
| 2025-05-14 | Buy | Topper James N | Director | 6,300 | $3.32 | $20.9K | 1 |
| 2025-05-13 | Buy | Topper James N | Director | 1,120 | $3.16 | $3.5K | 1 |
| 2025-05-12 | Buy | Topper James N | Director | 12,601 | $3.04 | $38.3K | 1 |
| 2025-05-09 | Buy | Topper James N | Director | 35,602 | $3.22 | $114.5K | 2 |
| 2025-05-07 | Buy | Parikh Asit | Director | 5,000 | $2.40 | $12.0K | 1 |
| 2025-05-06 | Buy | Parikh Asit | Director | 5,000 | $2.60 | $13.0K | 1 |
| 2025-04-07 | Sell | Henderson Molly | CFO | 3,678 | $4.55 | $16.7K | 1 |
| 2025-03-13 | Buy | Parikh Asit | Director | 10,000 | $4.42 | $44.2K | 1 |
| 2025-01-21 | Sell | Curran Terrie | CEO | 19,109 | $6.59 | $125.9K | 1 |
| 2025-01-21 | Sell | Nabulsi Azmi | COO | 7,886 | $6.59 | $52.0K | 1 |
| 2025-01-21 | Sell | Henderson Molly | CFO | 6,583 | $6.59 | $43.4K | 1 |
| 2024-12-19 | Sell | Henderson Molly | CFO | 1,291 | $8.00 | $10.3K | 1 |
| 2024-12-19 | Sell | Nabulsi Azmi | COO | 1,118 | $8.00 | $8.9K | 1 |
| 2024-12-13 | Buy | KARBE FRANK | Director | 12,500 | $7.93 | $99.1K | 1 |
| 2024-12-13 | Buy | Parikh Asit | Director | 10,000 | $8.12 | $81.2K | 1 |
| 2024-07-15 | Sell | Curran Terrie | CEO | 33,848 | $11.72 | $396.7K | 1 |
| 2024-07-15 | Sell | Nabulsi Azmi | COO | 10,901 | $11.72 | $127.8K | 1 |
| 2024-07-15 | Sell | Henderson Molly | CFO | 4,325 | $11.72 | $50.7K | 1 |
| 2024-04-08 | Sell | Henderson Molly | CFO | 3,435 | $11.10 | $38.1K | 1 |
| 2024-03-22 | Sell | Curran Terrie | CEO | 16,851 | $9.11 | $153.5K | 1 |
| 2024-01-24 | Sell | TAKEDA PHARMACEUTICAL CO LTD | 10% owner | 3,703,703 | $8.10 | $30.0M | 1 |
| 2024-01-19 | Sell | Henderson Molly | CFO | 6,307 | $7.75 | $48.9K | 1 |
| 2023-11-20 | Sell | Henderson Molly | CFO | 2,127 | $7.24 | $15.4K | 1 |
| 2023-11-08 | Buy | Parikh Asit | Director | 2,500 | $7.80 | $19.5K | 1 |
| 2023-11-07 | Buy | Parikh Asit | Director | 4,000 | $7.76 | $31.0K | 1 |
| 2023-11-06 | Buy | Parikh Asit | Director | 1,000 | $8.04 | $8.0K | 1 |
| 2023-11-01 | Sell | Henderson Molly | CFO | 12,492 | $8.88 | $110.9K | 2 |
| 2023-06-02 | Sell | Henderson Molly | CFO | 1,960 | $11.41 | $22.4K | 1 |
| 2023-05-22 | Sell | Henderson Molly | CFO | 2,110 | $12.87 | $27.2K | 1 |
| 2023-04-11 | Buy | Nabulsi Azmi | COO | 10,000 | $8.26 | $82.6K | 1 |
| 2023-04-10 | Buy | Parikh Asit | Director | 1,000 | $7.55 | $7.6K | 1 |
| 2023-04-06 | Buy | Curran Terrie | CEO | 12,919 | $7.82 | $101.0K | 1 |
| 2023-04-06 | Sell | Henderson Molly | CFO | 3,439 | $7.27 | $25.0K | 1 |
| 2023-03-01 | Sell | Henderson Molly | CFO | 2,032 | $8.53 | $17.3K | 1 |
| 2023-03-01 | Sell | Curran Terrie | CEO | 1,436 | $8.54 | $12.3K | 1 |
| 2023-02-13 | Buy | Parikh Asit | Director | 5,000 | $7.73 | $38.6K | 1 |
| 2023-01-20 | Sell | Curran Terrie | CEO | 5,821 | $8.20 | $47.7K | 1 |
| 2023-01-12 | Buy | Parikh Asit | Director | 5,000 | $7.00 | $35.0K | 1 |
| 2022-11-21 | Sell | Henderson Molly | CFO | 2,159 | $9.60 | $20.7K | 1 |
| 2022-11-21 | Sell | Curran Terrie | CEO | 1,526 | $9.60 | $14.6K | 1 |
| 2022-05-16 | Buy | Nabulsi Azmi | COO | 20,000 | $8.16 | $163.2K | 1 |
| 2022-05-13 | Buy | Curran Terrie | CEO | 20,500 | $7.41 | $151.9K | 1 |
| 2022-05-12 | Buy | Parikh Asit | Director | 12,500 | $8.00 | $100.0K | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD | 10% owner | $0 | $30.0M | 2024-01-24 |
| Curran Terrie | CEO | $252.9K | $750.8K | 2025-01-21 |
| Henderson Molly | CFO | $0 | $447.0K | 2025-04-07 |
| Nabulsi Azmi | COO | $245.8K | $188.7K | 2025-01-21 |
| Parikh Asit | Director | $390.2K | $0 | 2025-05-07 |
| Topper James N | Director | $191.9K | $0 | 2025-05-21 |
| KARBE FRANK | Director | $99.1K | $0 | 2024-12-13 |
| Breedlove Robert Charles | Other officer | $0 | $26.8K | 2025-11-03 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2023-04-06 → 2023-04-11 | 3 | $191.2K | 55 | +58.6% (+55.4% raw) | +60.2% (+68.7% raw) | +21.2% (+20.1% raw) | closed |
| 2022-05-12 → 2022-05-16 | 3 | $415.1K | 61 | -19.5% (-28.4% raw) | +22.3% (+32.1% raw) | +14.1% (+18.9% raw) | closed |
| 2019-10-29 | 3 | $40.2M | 43 | -25.9% (-22.8% raw) | -45.6% (-53.4% raw) | -46.3% (-50.1% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.